Kolmar BioTech. Inc.
KKRX:2153802,075.00
KRW
-40.00
(-1.89%)
ISIN
KR7215380007
Return %
Stock
S&P 500
1Y
19.25
14.20
3Y
11.86
81.12
5Y
-63.91
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Byung-Nyeon Cheon
- Full Time Employees
- 127
- Sector
- Process industries
- Industry
- Agricultural commodities/Milling
- Address
- Hwaseong-si South Korea
- IPO Date
- May 18, 2015
- Website
- woojungbio.kr
- Similar Companies
- Business
- Kolmar BioTech. Inc. is a South Korea-based biotechnology and life sciences infrastructure company specializing in non-clinical contract research organization services, biopharmaceutical facility engineering, biocontainment solutions, and open-innovation biotechnology incubation. Founded in 1989 and headquartered in Hwaseong-si, Gyeonggi-do, South Korea, the company operates primarily across the South Korean domestic market and international life sciences sectors as a publicly traded affiliate of Kolmar Holdings Co., Ltd. on the KOSDAQ exchange. Kolmar BioTech conducts operations through three core business segments: Contract Research Organization Services, Engineering and Construction Infrastructure, and the LAB CLOUD Open Innovation Platform. The company provides a comprehensive portfolio of products and services, including non-clinical in vivo and in vitro efficacy evaluations across oncology, metabolic disorders, neurodegenerative conditions, and immunology; preclinical safety and toxicity assessments conducted within AAALAC-accredited laboratory animal facilities; pharmacokinetic and pharmacodynamic analysis; histological, pathological, and biomarker testing; turnkey engineering, design, and construction of pharmaceutical Good Manufacturing Practice facilities and Biosafety Level laboratories; cleanroom environmental control systems; laboratory animal housing equipment including Individually Ventilated Cage systems and automated feeding systems; and infection control solutions featuring Vaporized Hydrogen Peroxide sterilization equipment, biological indicators, and decontamination systems. Through its LAB CLOUD initiative, the company offers shared high-end laboratory infrastructure, research instrumentation, and acceleration services for biotechnology startups and pharmaceutical developers. In recent corporate developments, Kolmar Holdings acquired a controlling interest in the enterprise in 2026 to integrate the company into the broader Kolmar Group life sciences network. Following the acquisition, the company executed an official corporate name change from Woojung Bio, Inc. to Kolmar BioTech. Inc. in July 2026, realigned its strategic operations to link its open-innovation drug development platform with group-wide research initiatives, expanded its non-clinical testing capacity, and entered into multiple preclinical research partnerships with emerging therapeutic biotechnology firms.